Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Emerging prognostic factors in diffuse large B cell lymphoma.

Randy D Gascoyne1

  • 1Department of Pathology & Laboratory Medicine, BC Cancer Agency & the University of British Columbia, 600 W. 10th Avenue, Vancouver, BC V5Z 4E6, Canada. rgascoyn@bccancer.bc.ca

Current Opinion in Oncology
|August 18, 2004
PubMed
Summary

Novel biomarkers are improving the understanding and prediction of outcomes in diffuse large B cell lymphoma (DLBCL). Gene expression and monoclonal antibody studies are key to refining prognostic models beyond the International Prognostic Index.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population.

Blood·2022
Same author

The outcome of older adults with classic Hodgkin lymphoma in British Columbia.

Blood advances·2022
Same author

Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma.

The Journal of clinical investigation·2022
Same author

A gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma.

Blood·2021
Same author

Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach.

Blood advances·2021
Same author

MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.

Haematologica·2021

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Diffuse large B cell lymphoma (DLBCL) is a heterogeneous lymphoma with varied clinical and biological features.
  • Accurate prognostic factors are crucial for patient management, but current biomarkers present challenges.
  • Gene expression studies and monoclonal antibodies offer new avenues for biomarker discovery.

Purpose of the Study:

  • To review recent advancements in novel biomarkers for DLBCL.
  • To discuss the integration of these biomarkers into current prognostic models.

Main Methods:

  • Analysis of gene expression data using microarrays.
  • Development and validation of monoclonal antibody reagents for protein expression.
  • Integration of molecular data with existing clinical and cytogenetic information.

Related Experiment Videos

Main Results:

  • Microarray analyses have significantly advanced biomarker understanding in non-Hodgkin lymphomas.
  • Thousands of genes can be analyzed, providing extensive data for new outcome predictors.
  • Existing monoclonal antibodies facilitate validation and potential clinical translation of biomarkers.

Conclusions:

  • A molecular classification of DLBCL is now established.
  • This classification, alongside morphology and cytogenetics, enables more accurate subtyping.
  • Novel biomarkers should be incorporated into prognostic models to enhance risk stratification beyond the International Prognostic Index.